he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源位址
上一页:老年人癫痫病因有哪些
下一页:全面性癫痫的不止研究
- 2022-05-05癫痫病癫痫时的紧急护理
- 2022-05-02癫痫病的哮喘有什么-
- 2022-04-212013年国际抗癫痫联合会抗癫痫药性使用指南
- 2022-04-13Medpage Today:不同类型的抗癫痫药物更有利
- 2022-04-12【健康科普】溢液不容忽视,发现溢液应该这样做
- 2022-04-11预测癫痫患者再入院风险
- Medpage Today:不同类型的抗癫痫药物更有利
- 【健康科普】溢液不容忽视,发现溢液应该这样做
- 预测癫痫患者再入院风险
- 癫痫发作对中风患者静脉溶栓的长期转移有效
- 癫痫治疗障碍仍难以克服
- 月经性癫痫患者妊娠期癫痫控制更好
- 女性最敏感的十个诱人部位(5)
- PLoS ONE:新的合成蛋白能快速激活免疫系统抵抗流感
- A&R: Semaphorin3B 在血清诱导的关节炎模型中发挥核心作用,减少类风湿性关节炎患者
- 特发性癫痫大发作药物治疗的首选
- 脑梗死的症状是什么有这些前兆要谨慎
- 儿童癫痫的早期症状 癫痫的原因
- FDA批准Aptiom用于治疗患者癫痫发作
- 月经期间预防什么,避免细菌感染
- 甲硝唑 VS 替硝唑,只是一字之差吗?
- BMJ:研究避孕对生育能力的影响
- 癫痫猝死:凶手是谁?
- 【用药情报站】临床应用应听取各种药种药物禁忌证?
- 2015 神经系统疾病诊疗进展
- UCB的Vimpat癫痫新适应症在美国获批
- 不注意这些问题,吃多少药都没用!
- 灼烧综合征的原因不容忽视治疗
- 美国神经病学协会的新指南帮助医生HIV癫痫药物更适合患者
- 三庚酸酯可治疗1型转运体缺陷综合征
- 自身免疫病也可以免疫治疗
- 被WHO推荐,IVD国产替代品在结核病诊断领域取得了新的成果
- 治疗脑炎后遗症的方法有哪些?
- 经期要注意 有些药物进食品不可进食
- 20130318东南食来运转片段:猪血豆腐汤的做法
- 【用药问答】控制癫痫患者再抽搐, 可搭配的药物不包括?
- 小叶的好处 小叶这些本领你都知道吗
- 癫痫病的以前症状是什么样的
- 癫痫病是什么病 癫痫如何治疗相比较好
- 失眠不好怎么办 失眠不好竟然会致命(2)
- 20130821山东卫视养生:许新升讲癫痫的侵害
- 千万别忽视孩童癫痫病症状
- 癫痫病发病究竟是早就
- 什么是帕金森氏症 患者如何进行心理调节
- 女性癫痫遗传吗 癫痫病人怎样生健康宝宝
- 女性体检 每星期体检摆脱妇科亚健康